Physician profile
Jason Barton
NPI 1407859218
$5,275.29
in general payments reported to CMS, 2019-2025
25 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2022: $538 · 2023: $2,115 · 2024: $1,443 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,579 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,578.96 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,449.38 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $658.67 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $656.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $464.98 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Corcept Therapeutics | $307.02 | 2023-2025 | Korlym |
| Amgen INC. | $273.91 | 2022-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $234.94 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $231.96 | 2022-2025 | |
| Astellas Pharma US INC | $177.38 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $143.60 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $91.30 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.85 | 2019-2025 | Jardiance, Tradjenta |
| Nestle Healthcare Nutrition INC. | $81.86 | 2023 | |
| Novartis Pharmaceuticals Corporation | $72.13 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.42 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.56 | 2023-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $40.54 | 2024-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $37.02 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $33.47 | 2022-2023 | Steglatro, Belsomra, Steglujan |
| E.R. Squibb & Sons, L.L.C. | $31.37 | 2022-2023 | |
| Dexcom, INC. | $22.49 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $19.17 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $16.79 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $13.99 | 2023 | |
| Mdd US Operations, LLC | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.